Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman1, Justin L. Roberts1, Lie Li1, David Finkelstein2, Alice Gibson1, Amarjit S. Chaudhry1, Erin G. Schuetz1, Jeffrey E. Rubnitz3, Hiroto Inaba3, and Sharyn D. Baker1

Abstract

Purpose: To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide.

Experimental Design: Steady-state pharmacokinetic studies of sorafenib and metabolites were conducted in 30 children and young adults (17 males; median age, 9.5 years) receiving sorafenib 150 mg/m2 or 200 mg/m2 twice daily. Sorafenib metabolism was evaluated in vitro at 10 μmol/L using a panel of purified human cytochrome P450 (CYP) enzymes. Sorafenib metabolism and CYP3A4 expression was evaluated in 52 human liver samples from donors of ≤20 years old. The drug–drug interaction potential between sorafenib and azole antifungal agents was evaluated in vitro and in vivo.

Results: No age-related differences in sorafenib apparent oral clearance were observed. Mean sorafenib N-oxide metabolite ratio was 0.27 ± 0.14. In children of ≤10 years of age, boys had approximately 2-fold higher N-oxide ratios than girls (0.40 ± 0.15 vs. 0.22 ± 0.12, P = 0.026). Of the CYPs evaluated, sorafenib was exclusively metabolized to sorafenib N-oxide by CYP3A4. A trend for increased N-oxide formation in boys was observed in liver samples, which correlated with CYP3A4 mRNA expression. Posaconazole and voriconazole potently inhibited sorafenib N-oxide formation in vitro, and reduced sorafenib N-oxide formation in 3 children given sorafenib concurrent with azoles.

Conclusion: We have identified several factors affecting interpatient variability in sorafenib metabolism to the active N-oxide metabolite including age, sex, and concurrent treatment withazole antifungals. This knowledge may provide important considerations for the clinical use of sorafenib in children and possibly other kinase inhibitors undergoing CYP3A4-mediated metabolism. Clin Cancer Res; 18(20): 5788–95. ©2012 AACR.
Patients and Methods

Children and young adults with FLT3-ITD-positive AML were enrolled in the frontline trial AML08 (clinical trials.gov identifier NCT00908167) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide. Children and young adults with relapsed or refractory AML were enrolled to the trial RELHEM (clinical trials.gov identifier NCT00703820) and treated with sorafenib 200 mg/m² twice daily after Induction II therapy with cytarabine, daunorubicin, and etoposide.

Pharmacokinetic studies

Peripheral blood was collected on days 7 (RELHEM trial) or day 8 (AML08 trial) before and 2, 4.5, and 7.5 hours after sorafenib administration. Samples were centrifuged for 10 minutes at 3000 g and plasma was stored at −80°C until analysis. A blood sample was obtained pretreatment (trough) and throughout therapy from patients receiving sorafenib long term with concurrent azole antifungals. The concentration of sorafenib, sorafenib N-oxide, and sorafenib glucuronide was measured using a validated high-performance liquid chromatography-based method with tandem mass spectrometric detection as described in the Supplementary Materials. Average steady-state plasma concentration (Css,ave) for each analyte was estimated 2 ways: (i) as the mean concentration of the 4 samples collected on the specified day, because the concentration time profiles showed minimal fluctuations from maximum to minimum during the sampling interval; and (ii) as area under the curve (AUC) over the dosing interval of 12 hours (AUC0-12h) divided by the dosing interval. For the latter, AUC0-12h was calculated using the predose concentration as the 12 hour concentration as troughs should be constant at steady state. All trough concentrations were obtained within 30 minutes before administration of the dose. Values for Css,ave calculated by both methods were within 4.0%, 0.7%, and 3.5% of each other for sorafenib, sorafenib N-oxide, and sorafenib glucuronide, respectively.Css,ave values reported in this study were estimated using the first method described above. Steady-state sorafenib apparent oral clearance was estimated as sorafenib dosing rate (dose/dosing interval of 12 hours) divided by Css,ave and was normalized to body surface area. Metabolite ratios were determined as the metabolite Css,ave divided by sorafenib Css,ave.

In vitro studies

Sorafenib metabolism to sorafenib N-oxide by human CYP1A1, CYP1A2, CYP3A4, CYP3A5, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 was determined. Sorafenib metabolism to sorafenib glucuronide by human UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, and UGT2B15 was also assessed. The ability of azole antifungals to inhibit sorafenib CYP3A4- and UGT1A9-mediated metabolism was studied. Sorafenib CYP3A4- and UGT-mediated metabolism and CYP3A4 and UGT1A9 gene expression were determined in 52 human liver samples from donors 1 to 20 years old. Liver tissue was processed through the Liver Resource at St. Jude Children’s Research Hospital and was provided by the Liver Tissue Procurement and Distribution System (NIH Contract #N01-DK-9-2310) and by the Cooperative Human Tissue Network. Detailed descriptions of the in vitro experiments are found in the Supplementary Materials.

Statistical considerations

Comparisons of metabolite ratios or metabolite formation velocity between males and females within different age groups (<10 years and >10–20 years) were conducted using the nonparametric Wilcoxon rank-sum test. The age of 10 years was selected as an arbitrary cutoff for analysis to compare sorafenib metabolism between younger and older children. Data for gene expression in human liver samples were log2 transformed before comparisons in accordance with gene expression literature (8). Linear regression analysis was conducted to assess the correlation between sorafenib metabolic pathways (sorafenib N-oxide metabolic ratio vs. sorafenib glucuronide metabolite ratio); and CYP3A4 or UGT1A9 mRNA expression versus metabolite velocity. Interpatient variability was estimated as the coefficient of variation (CV), calculated as the SD divided by the mean and expressed as a percentage (CV%). Statistical significance was assigned if P < 0.05.
Results

Sorafenib pharmacokinetics and metabolism

Pharmacokinetic studies were conducted in 30 children and young adults (17 males, 13 females) with AML from November 2008 to January 2012. The median age was 9.5 years (range, 1 to 19 years). Six patients were treated with 150 mg/m² sorafenib and 24 patients with 200 mg/m². Individual patient demographics and steady-state pharmacokinetic parameters for sorafenib and metabolites are summarized in Supplementary Table S1. Mean steady-state sorafenib and metabolite concentration-time profiles at 150 mg/m² and 200 mg/m² are illustrated in Fig. 1. Mean sorafenib steady-state concentration was higher at 150 mg/m² than at 200 mg/m² (7.1 mg/L vs. 5.1 mg/L), which is likely due to extensive intersubject pharmacokinetic variability of sorafenib and the smaller number of children treated at the lower dose level (6 vs. 24). Mean ± SD steady-state sorafenib apparent oral clearance (CL/F) was 64 ± 37 mL/min/m² (CV%, 58%). No age-related differences in (CL/F) were observed, and mean CL/F was similar among males and females (males, 67 ± 43 vs. females, 60 ± 28 mL/min/m²; P = 0.983; Fig. 2).

Mean sorafenib N-oxide metabolite ratio was 0.27 ± 0.14. No sex-related differences in N-oxide metabolite ratio was observed between males and females (males, 0.26 ± 0.15 vs. females, 0.22 ± 0.10; P = 0.402; Supplementary Fig. S1A). Inspection of sorafenib N-oxide metabolite ratios as a function of age and sex uncovered a trend for higher sorafenib N-oxide conversion in boys than girls of 10 or less years old, which appeared to peak in boys between approximately 6 to 10 years of age (Fig. 3A). Boys had approximately 2-fold higher ratios than girls (males, 0.40 ± 0.15 vs. females, 0.22 ± 0.12; P = 0.026); metabolite ratios were similar among males and females older than 10 years (0.18 ± 0.021 vs. 0.23 ± 0.12, respectively; P = 0.061; Fig. 3B). Sorafenib N-oxide metabolite ratios were more variable in both boys and girls of 10 or less years (CV%, 39% and 59%, respectively) compared with those greater than 10 years of age (CV%, 11% and 20%, respectively).

Mean sorafenib glucuronide metabolite ratio was 0.30 ± 0.19, which did not vary significantly between males and females overall (P = 0.438; Supplementary Fig. S1B) or in either of the 2 age groups (P ≥ 0.370; Fig. 3C and D). Sorafenib glucuronide metabolite ratios were more variable in boys and girls in the younger age group (CV%, 71% and 70%, respectively) compared with children older than 10 years (CV%, 42% and 28%, respectively).
Sorafenib CYP- and UGT-mediated metabolism in vitro

To comprehensively determine the enzymes responsible for sorafenib metabolism, we assessed sorafenib metabolism in vitro using a panel of purified human CYP and UGT enzymes. Our results showed that CYP3A4 is the predominant isozyme responsible for sorafenib oxidation and UGT1A9 is primarily responsible for sorafenib glucuronidation (Supplementary Fig. S2). The apparent Km was 12.1 ± 0.71 μmol/L for CYP3A4-mediated oxidation and 3.6 ± 0.22 μmol/L for UGT1A9-mediated glucuronidation.

Azole antifungal agents, including ketoconazole, voriconazole, and posaconazole, inhibit CYP3A4 activity, and ketoconazole has also been shown to inhibit UGT1A9 (9, 10). Because cancer patients are commonly treated with azoles for the prevention or treatment of invasive fungal infections, we compared the inhibitory effects of azoles on sorafenib metabolism. Azole antifungals inhibited CYP3A4-mediated sorafenib N-oxide formation with apparent Ki values of 0.16 ± 0.09 μmol/L, 0.38 ± 0.09 μmol/L, and 35.7 ± 10.7 μmol/L for ketoconazole, posaconazole, and voriconazole, respectively (Supplementary Fig. S3). Ketoconazole inhibited sorafenib glucuronidation by UGT1A9 with an apparent Ki of 2.2 μmol/L (Supplementary Fig. S4).

Effect of treatment withazole antifungals on sorafenib N-oxide production

One 6-year-old girl enrolled on the RELHEM protocol was receiving antifungal prophylaxis with posaconazole 140 mg every 6 hours. This patient had the lowest sorafenib N-oxide metabolite ratio in the entire population (0.05; Supplementary Table S1). No other patients were documented to have received treatment with azoles or other strong CYP3A4 inhibitors during the sorafenib pharmacokinetic study period. However, we assessed the effect of voriconazole on sorafenib metabolism in 2 children with FLT3-ITD-positive AML who received long-term treatment with sorafenib. The first patient was a 10-year-old boy treated with 2 courses on the RELHEM protocol. The N-oxide metabolite ratio on day 7 was 0.44 (Fig. 4). While waiting for hematopoietic stem cell transplantation (HSCT), he developed Rous sarcoma virus infection and then received single-agent sorafenib 200 mg once daily for approximately 8 months. During this time, the N-oxide metabolite ratio on day 103 was 0.43. Shortly thereafter, antifungal prophylaxis with oral voriconazole 150 mg twice daily was started. With persistent marrow infiltration with leukemic cells, the sorafenib dose was increased to 200 mg twice daily on day 321. On days 338 and 383, N-oxide metabolite ratio was dramatically reduced to 0.06 and 0.05, respectively, compared with previous values without concurrent voriconazole. The second patient was a 10-year-old boy treated with 1 course of sorafenib 200 mg/m² after Induction II on the AML08 protocol. On day 15, the N-oxide metabolite ratio was 0.29. He received a HSCT and relapsed 15 months later. On day 554, sorafenib 200 mg once daily was initiated with concurrent oral voriconazole 150 mg twice daily. On days 575 and 607, the N-oxide metabolite ratio was dramatically reduced to 0.05 and 0.09, respectively, when compared with previous values in the absence of voriconazole (Fig. 4). Consistent with the in vitro data, sorafenib N-oxide metabolite ratio was greatly reduced upon cotreatment with posaconazole and voriconazole.
Sorafenib metabolism in human liver samples

The effects of age and sex on sorafenib CYP- and UGT-mediated metabolism were studied in microsomes (HLM) isolated from 52 human liver samples. CYP-mediated metabolism to sorafenib N-oxide as a function of age and sex is illustrated in Fig. 5A. A nonsignificant trend for increased sorafenib N-oxide formation was observed in males compared with females in the 10 to 15 year age group (median, 1.1 vs. 1.5 log\[\text{mol/L/min/mg HLM}\]; Fig. 5B). Analysis of sorafenib glucuronidation showed no notable trends for either age or sex (Supplementary Fig. 5A and B).

To determine whether CYP-mediated sorafenib metabolism corresponded with enzyme mRNA expression, we used quantitative PCR analysis to measure liver CYP3A4 mRNA expression. Similar to sorafenib N-oxide production, a nonsignificant trend for increased CYP3A4 expression was observed in males compared with females in the 10 to 15 year age group (median, 16.8 vs. 13.0 log\[2\] [transcript/ng RNA]; Fig. 5C and D). CYP3A4 mRNA expression was correlated with sorafenib N-oxide production ($r^2 = 0.33; P < 0.0001$), suggesting that the variability observed in sorafenib N-oxide formation in liver samples was partially due to variability in CYP3A4 expression. In contrast, UGT1A9 mRNA expression displayed no trends with regard to age and sex and did not correlate with the level of sorafenib glucuronidation (Supplementary Fig. 5C–E).
Discussion

In this study, we describe a comprehensive characterization of sorafenib metabolism in vitro and in vivo in children with AML. Of a panel of CYP and UGT enzymes evaluated, we showed that sorafenib is almost exclusively metabolized to sorafenib N-oxide by CYP3A4 and to sorafenib glucuronide by UGT1A9. Although no age-related differences in sorafenib steady-state apparent oral clearance were seen, we observed a higher rate of sorafenib conversion to the active metabolite sorafenib N-oxide in children compared with that reported previously in adults with cancer (6, 7). To our knowledge, we report the first analysis of sorafenib glucuronidation in cancer patients. On average, sorafenib glucuronide and N-oxide metabolite ratios were similar (~0.30). We showed in vitro that the clinically useful azole antifungals posaconazole and voriconazole potently inhibited sorafenib metabolism to sorafenib N-oxide, but were weak inhibitors of sorafenib glucuronidation. A drug–drug interaction was shown in vivo, where both posaconazole and voriconazole reduced N-oxide production to negligible levels.

The majority of kinase inhibitors that are approved for the treatment of cancer are primarily metabolized by CYP3A4 to an active metabolite (11–14). In general, active metabolites of kinase inhibitors represent approximately 10% or less of exposure to parent drug. One exception is sunitinib, where the active metabolite N-desethyl-sunitinib accounts for 30% to 50% of total pharmacologic activity in cancer patients (15–17). Here, we show that sorafenib provides another exception to the other kinase inhibitors in that we observed a mean 27% conversion to sorafenib N-oxide in children ranging in age from 1 to 19 years, and even higher conversion (40%) in boys of 10 or less years. In view of the circulating concentrations of sorafenib N-oxide in children (mean ~2–3 μmol/L at sorafenib 200 mg/m²), it is believed to contribute significantly to sorafenib-induced antitumor activity.

The maturation of drug-metabolizing enzymes during childhood development is considered one of the main factors accounting for age-associated changes in drug metabolism and has been extensively studied (18). In vitro, CYP3A activity is low before birth, increases rapidly after birth, and reaches a peak in infants to levels slightly higher than those in adults (18, 19). However, in vivo evaluations of CYP3A4 activity have yielded inconsistent results. For
example, one study showed no differences in CYP3A activity among older infants, children, and adults (20), whereas another study showed that CYP3A4 activity was lower in infants and children up to 2 years but higher in older children 3 to 13 years when compared with adults (21).

To gain further insight into age-associated changes in sorafenib N-oxide formation, we evaluated CYP3A4 gene expression and sorafenib metabolism in a large cohort of human liver samples from children of less than 20 years old. We observed substantial variability in metabolism to sorafenib N-oxide across all age groups, and the same trend for higher conversion in boys. However, peak N-oxide conversion was observed between the ages of 10 and 15 years in vitro instead of 6 to 10 years in our patient population. However, both our in vitro and in vivo findings are in line with those from a separate cohort of liver samples, where a trend for higher CYP3A4-mediated testosterone and midazolam metabolism was observed in males versus females less than 10 years as well as in a group aged 10 to 19 years (22). We also showed that CYP3A4 mRNA expression was correlated with sorafenib N-oxide formation. Thus, differential activity of nuclear receptors and/or other proteins known to regulate CYP3A4 transcription, such as PXR (23), CAR (24), and HNF4α (25), could explain the interpatient differences in sorafenib N-oxidation in the liver samples. Discrepancies in peak occurrence of sorafenib N-oxide formation between our patient population and liver samples could also be because of differences in the timing of pubertal maturation. It is known that changes in growth hormone and sex steroids that occur during adolescence can affect the expression of drug-metabolizing enzymes (26, 27). The observed enhanced N-oxide formation in boys compared with girls may suggest a preferential effect of androgens on sorafenib metabolism, as has been described previously for carbamazepine epoxidation by CYP3A4 (28). Ultimately, there are limitations to evaluating drug metabolizing enzyme expression and activity in frozen human liver samples such as the lack of adequate documentation of concurrent medications and comorbidities of the donor, although an attempt was made to document these factors in the liver population tested.

Less is known about developmental changes in UGT1A9. Analysis of livers from 16 pediatric patients aged 6 to 24 months showed that UGT1A9 mRNA expression was lower in infants compared with adult livers of more than 25 years of age (29). Although no obvious age-related trends in sorafenib glucuronidation were observed in our pediatric population or liver samples, glucuronidation rates, as well as sorafenib N-oxide formation, appeared the most variable in younger children (Fig. 2C). The latter observation suggests that developmental or maturational changes in drug metabolizing enzymes likely affect sorafenib metabolism.

A drug–drug interaction between azole antifungals and sorafenib was shown both in vitro and in vivo. In several cases of children receiving concurrent posaconazole or voriconazole with sorafenib, we observed significantly reduced conversion of sorafenib to sorafenib N-oxide. Because sorafenib doses were changing throughout the clinical time course, we could not determine if sorafenib exposure was altered by cotreatment with azoles in these particular cases. In healthy subjects, ketoconazole inhibited sorafenib metabolism to the N-oxide, but it had no effect on sorafenib plasma clearance (3). Therefore, posaconazole and voriconazole are not expected to significantly alter sorafenib exposure. In light of the potential contribution of sorafenib N-oxide to antitumor activity and the ability of azoles antifungals to inhibit N-oxide production in vitro, the use of alternative antifungal agents should be considered with sorafenib therapy unless azole antifungals are medically indicated.

In conclusion, we have identified several factors affecting interpatient variability in sorafenib metabolism to its active metabolite sorafenib N-oxide including age, sex, and concurrent treatment with azole antifungals. Because the active metabolite is likely to contribute to antitumor activity, this knowledge may provide important considerations for the effective use of sorafenib in childhood AML and possibly other pediatric cancers. The effect of ontogeny on CYP3A4-mediated metabolism may also be relevant to the clinical use of other kinase inhibitors.

Disclosure of Potential Conflicts of Interest

H. Inaba receives research funding from Bayer Pharmaceutical. No potential conflicts of interests were disclosed by the other authors.

Authors’ Contributions

Conception and design: E.I. Zimmerman, J.L. Roberts, A.S. Chaudhry, S.D. Baker


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.I. Zimmerman, J.L. Roberts, L. Li, A.A. Gibson, A.S. Chaudhry, E.G. Schuetz, J. Rubinitz, H. Inaba

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.I. Zimmerman, J.L. Roberts, L. Li, D. Finkelestein, A.S. Chaudhry, S.D. Baker

Writing, review, and/or revision of the manuscript: E.I. Zimmerman, J.L. Roberts, A.S. Chaudhry, E.G. Schuetz, J. Rubinitz, H. Inaba, S.D. Baker

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.I. Zimmerman, H. Inaba

Study supervision: S.D. Baker

Grant Support

Supported by Grants No. CA138744, CA201765, and CA203944 from the US Public Health Services, NIH/NIGMS Grant R01 GM094418, and by the American Lebanese Syrian Associated Charities.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 20, 2012; revised August 7, 2012; accepted August 21, 2012; published OnlineFirst August 27, 2012.

Published OnlineFirst August 27, 2012; DOI: 10.1158/1078-0432.CCR-12-1967

References


Ontogeny and Sorafenib Metabolism


# Ontogeny and Sorafenib Metabolism

Eric I. Zimmerman, Justin L. Roberts, Lie Li, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-1967</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2012/08/27/1078-0432.CCR-12-1967.DC1">http://clincancerres.aacrjournals.org/content/suppl/2012/08/27/1078-0432.CCR-12-1967.DC1</a></td>
</tr>
</tbody>
</table>

| Cited articles | This article cites 29 articles, 15 of which you can access for free at: http://clincancerres.aacrjournals.org/content/18/20/5788.full#ref-list-1 |
| Citing articles | This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/18/20/5788.full#related-urls |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |